Le Lézard
Classified in: Health, Business

Optimi Health Announces Re-Appointments to Board of Directors

VANCOUVER, British Columbia, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), is pleased to announce that Mr. Bryan Safarik, Mr. Jacob Safarik, Mr. Jon Schintler, Mr. Dane Stevens, and Mr. JJ Wilson have been re-elected to the Board of Directors following the Company's Annual General Meeting held January 9, 2023. The Company would like to thank departing director Mr. Michael Stier for his service and wishes him well in his future endeavours. Optimi shareholders also re-appointed Smythe LLP as auditor and re-approved the Company's Equity Incentive Plan.


Optimi Health Corp. is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company's goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimi's products are grown at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia, making it the largest psilocybin and MDMA cultivator in North America.


Michael Kydd
Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121


This news release contains forward?looking statements and forward?looking information within the meaning of Canadian securities legislation (collectively, "forward?looking statements") that relate to Optimi's current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward?looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward?looking statements. No assurance can be given that these expectations will prove to be correct and such forward?looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward?looking statements pertaining to activities proposed to be conducted under the Company's approved Health Canada dealer's licence and associated business related to Psilocybin, Psilocin, other psychedelic substances, some being synthetically formulated, and Optimi's plans, focus and objectives.

Forward?looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward?looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID?19 pandemic and other factors set forth under "Forward?Looking Statements" and "Risk Factors" in the Company's Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi's profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward?looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward?looking statement.

Any forward?looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

These press releases may also interest you

at 14:01
Prominently featured in The Inner Circle, Jason Chouake is acknowledged as a Most Trusted Healthcare Professional for his contributions to the field of Dermatology. Dr. Chouake pursued higher education at Yeshiva University where he earned a...

at 14:00
The "Animal Drug Compounding Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global animal drug compounding market is experiencing significant growth, with projections indicating an increase from $1.44...

at 13:50
Ulike, the leading at-home IPL hair removal brand, is supporting Polycystic Ovary Syndrome (PCOS) warriors in honor of PCOS Awareness Month (September) with their We See You campaign. Ulike is dedicated to raising awareness around and providing...

at 13:45
Incyte today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin....

at 13:45
The "Dermatology Lasers Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global dermatology lasers market is on the rise, with predictions indicating an increase from $1.96 billion in 2022 to $2.07 billion...

at 13:31
Tampa General Hospital (TGH) has been named a 2023 Tampa Bay Inno Award honoree by the Tampa Bay Business Journal. Tampa General is one of 23 local organizations honored this year and is recognized in the Partnerships category for its innovative...

News published on and distributed by: